- Home
- GLPG vs WERN Comparison
GLPG vs WERN Comparison
Compare GLPG & WERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- WERN
- Stock Information
- Founded
- GLPG 1999
- WERN 1956
- Country
- GLPG Belgium
- WERN United States
- Employees
- GLPG N/A
- WERN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- WERN Trucking Freight/Courier Services
- Sector
- GLPG Health Care
- WERN Industrials
- Exchange
- GLPG Nasdaq
- WERN Nasdaq
- Market Cap
- GLPG 2.1B
- WERN 1.7B
- IPO Year
- GLPG 2005
- WERN N/A
- Fundamental
- Price
- GLPG $33.10
- WERN $27.63
- Analyst Decision
- GLPG Sell
- WERN Hold
- Analyst Count
- GLPG 4
- WERN 13
- Target Price
- GLPG $25.33
- WERN $31.08
- AVG Volume (30 Days)
- GLPG 168.5K
- WERN 574.0K
- Earning Date
- GLPG 10-29-2025
- WERN 10-28-2025
- Dividend Yield
- GLPG N/A
- WERN 2.02%
- EPS Growth
- GLPG N/A
- WERN N/A
- EPS
- GLPG N/A
- WERN 0.85
- Revenue
- GLPG $323,674,692.00
- WERN $2,965,642,000.00
- Revenue This Year
- GLPG N/A
- WERN $1.11
- Revenue Next Year
- GLPG N/A
- WERN $5.68
- P/E Ratio
- GLPG N/A
- WERN $32.56
- Revenue Growth
- GLPG 5.43
- WERN N/A
- 52 Week Low
- GLPG $22.36
- WERN $23.02
- 52 Week High
- GLPG $33.86
- WERN $42.48
- Technical
- Relative Strength Index (RSI)
- GLPG 57.54
- WERN 45.02
- Support Level
- GLPG $31.49
- WERN $27.27
- Resistance Level
- GLPG $33.63
- WERN $29.02
- Average True Range (ATR)
- GLPG 0.68
- WERN 0.79
- MACD
- GLPG 0.01
- WERN -0.11
- Stochastic Oscillator
- GLPG 81.82
- WERN 16.53
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.